ASEAN to Build its own CDC to Mitigate Another Pandemic Risk
ASEAN members agreed on setting up the ASEAN Center for Public Health Emergencies and Emerging Diseases (ACPHEED) at the 15th...
Iskandar Shahril
Sinclair Pharma Partners with Vanguard Aesthetics to Launch Silhouette Soft in Malaysia
Sinclair Pharma, a global pharmaceutical brand providing aesthetic dermatology and collagen solutions is collaborating exclusively with Vanguard Aesthetics to bring...
HistoIndex Welcomes Life Sciences and MedTech Visionary, David John Jeans CBE, to Board of Directors
HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, is very pleased to announce the appointment of Dr. David...
Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China
Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics...
Ginkgo Bioworks and First Serv Announce Plans to Develop and Implement Innovative Global Biosecurity Capabilities in Qatar
Ginkgo Bioworks, the leading horizontal platform for cell programming, and First Serv, a Qatari investment holding company, today announced that...
Watsons and DOC2US Ink Regional Partnership Agreement
DOC2US, Malaysia’s first e-prescription service provider announced a strategic partnership with Watsons Malaysia, Malaysia's leading health and beauty retailer to...
GenScript ProBio Establishes Korean Legal Entity and Further Strengthens Cooperation in South Korea and APAC Region
On the May 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO company from GenScript Biotech Corporation, today...
InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers
InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat...
Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with...
OMRON Healthcare Unveils Long-term Corporate Vision, “Going for ZERO, Preventive Care for Health of Society”
In March 2022, OMRON Group announced a new long-term vision, "Shaping the Future 2030" (hereafter referred to as SF2030). In...
